Skip to main content
main-content
Top

Tip

Swipe om te navigeren naar een ander artikel

14-09-2017 | Original Article - E‑Learning | Uitgave 11/2017 Open Access

Netherlands Heart Journal 11/2017

Everolimus-eluting bioresorbable vascular scaffold in daily clinical practice: A single-centre experience

Tijdschrift:
Netherlands Heart Journal > Uitgave 11/2017
Auteurs:
W. S. Remkes, R. S. Hermanides, M. W. Kennedy, E. Fabris, E. Kaplan, J. P. Ottervanger, A. W. J. van ’t Hof, E. Kedhi
Belangrijke opmerkingen
W.S. Remkes and R.S. Hermanides contributed equally to this article.

Abstract

Background

Recent evidence has raised concerns regarding the safety of the everolimus-eluting bioresorbable vascular scaffold (E-BVS) (Absorb, Abbott Vascular, Santa Clara, CA, USA). Following these data, the use of this device has diminished in the Netherlands; however, daily practice data are limited. Therefore we studied the incidence of safety and efficacy outcomes with this device in daily clinical practice in a single large tertiary centre in the Netherlands.

Methods

All E‑BVS treated patients were included in this analysis. The primary endpoint was target lesion failure (TLF), a composite of cardiac death, target vessel non-fatal myocardial infarction (TV-MI) and clinically-driven target lesion revascularisation (TLR). The secondary endpoint was the incidence of definite scaffold thrombosis.

Results

Between October 2013 and January 2017, 105 patients were treated with 147 E‑BVS. This population contained 42 (40%) patients with diabetes mellitus and 43 (40.9%) undergoing treatment for acute coronary syndrome, and thus represents a high-risk patient cohort. Mean follow-up was 19.8 months. Intravascular imaging guidance during scaffold implantation was used in 64/105 (43.5%) patients. The primary endpoint (TLF) occurred in 3 (2.9%) patients. All-cause mortality and cardiac mortality occurred in 2 (2%) and 0 (0%) patients respectively. TV-MI occurred in 2 patients (1.9%): both were periprocedural and not related to the BVS implantation. TLR occurred in 1 patient (1.0%) during follow-up. No definite scaffold thrombosis occurred during follow-up.

Conclusion

This single-centre study examining the real-world experience of E‑BVS implantation in a high-risk population shows excellent procedural safety and long-term clinical outcomes.

Onze productaanbevelingen

Netherlands Heart Journal

Het Netherlands Heart Journal wordt uitgegeven in samenwerking met de Nederlandse Vereniging voor Cardiologie en de Nederlandse Hartstichting. Het tijdschrift is Engelstalig en wordt gratis beschikbaa ...

Literatuur
Over dit artikel

Andere artikelen Uitgave 11/2017

Netherlands Heart Journal 11/2017 Naar de uitgave

Editor’s Comment

Resuscitation on the pitch